DEVELOPMENT OF A BIOCOMPATIBLE PRODUCT FOR FICILI_2551 INJURY THERAPY (Q2034425)

From EU Knowledge Graph
Revision as of 15:08, 23 December 2021 by DG Regio (talk | contribs) (‎Changed label, description and/or aliases in nl, and other parts: Adding Dutch translations)
Jump to navigation Jump to search
Project Q2034425 in Italy
Language Label Description Also known as
English
DEVELOPMENT OF A BIOCOMPATIBLE PRODUCT FOR FICILI_2551 INJURY THERAPY
Project Q2034425 in Italy

    Statements

    0 references
    39,920.0 Euro
    0 references
    79,839.95 Euro
    0 references
    50.0 percent
    0 references
    10 November 2017
    0 references
    30 June 2021
    0 references
    ZETA RESEARCH S.R.L.
    0 references
    0 references

    45°40'37.52"N, 13°45'12.31"E
    0 references
    IL PRESENTE PROGETTO RIGUARDA LO SVILUPPO E IL TESTO IN VITRO E IN VIVO IN MODELLI PRE-CLINICI UN PRODOTTO TERAPEUTICO INNOVATIVO BASATO SULLA COMBINAZIONE DI TRE ELEMENTI (MATRICE EXTRACELLULARE, CELLULE ENDOTELIALI E FATTORI DI CRESCITA), UTILIZZANDO IL BIOREATTORE AUTOMATIZZATO NANT 001 AL FINE DI CONSENTIRE LA STANDARDIZZAZIONE DEL PROCESSO, NONCHé LA RIDUZIONE DI TEMPI E COSTI DEL PROCESSAMENTO DELLE CELLULE ENDOTELIALI AUTOLOGHE (ISOLATE DA UNA BIOPSIA DELLO STESSO PAZIENTE IN CUI VERRAN (Italian)
    0 references
    THIS PROJECT CONCERNS THE DEVELOPMENT AND THE IN VITRO AND IN VIVO MODELS IN PRE-CLINICAL MODELS OF AN INNOVATIVE THERAPEUTIC PRODUCT BASED ON THE COMBINATION OF THREE ELEMENTS (EXTRACELLULAR MATRIX, ENDOTHELIAL CELLS AND GROWTH DRIVERS), USING THE AUTOMATIC NANT 001 BIOREACTOR IN ORDER TO ALLOW STANDARDISATION OF THE PROCESS, AVOIDANCE OF TIME AND COST OF THE PROCESS OF AUTOLOGOUS ENDOTHELIAL CELLS (ISOLATED BY A PATIENT BIOPSY IN THE SAME PATIENT WHERE VERRAN (English)
    0 references
    CE PROJET CONCERNE LE DÉVELOPPEMENT ET LE TEXTE IN VITRO ET IN VIVO DANS DES MODÈLES PRÉCLINIQUES D’UN PRODUIT THÉRAPEUTIQUE INNOVANT BASÉ SUR LA COMBINAISON DE TROIS ÉLÉMENTS (MATRICE EXTRACELLULAIRE, CELLULES ENDOTHÉLIALES ET FACTEURS DE CROISSANCE), EN UTILISANT LE BIORÉACTEUR AUTOMATISÉ NANT 001 AFIN DE PERMETTRE LA NORMALISATION DU PROCESSUS, AINSI QUE LA RÉDUCTION DU TEMPS ET DU COÛT DU TRAITEMENT DES CELLULES ENDOTHÉLIALES AUTOLOGUES (ISOLÉES D’UNE BIOPSIE DU MÊME PATIENT DANS LAQUELLE IL SERA (French)
    16 December 2021
    0 references
    DIT PROJECT HEEFT BETREKKING OP DE ONTWIKKELING EN TEKST IN VITRO EN IN VIVO IN PREKLINISCHE MODELLEN VAN EEN INNOVATIEF THERAPEUTISCH PRODUCT GEBASEERD OP DE COMBINATIE VAN DRIE ELEMENTEN (EXTRACELLULAIRE MATRIX, ENDOTHEELCELLEN EN GROEIFACTOREN), WAARBIJ GEBRUIK WORDT GEMAAKT VAN DE GEAUTOMATISEERDE BIOREACTOR NANT 001 OM DE STANDAARDISATIE VAN HET PROCES MOGELIJK TE MAKEN, EVENALS DE VERMINDERING VAN DE TIJD EN DE KOSTEN VAN DE VERWERKING VAN AUTOLOGE ENDOTHEELCELLEN (GEÏSOLEERD UIT EEN BIOPSIE VAN DEZELFDE PATIËNT WAARIN HET ZAL WORDEN UITGEVOERD) (Dutch)
    23 December 2021
    0 references

    Identifiers

    D93D19000190007
    0 references